Viatris Inc. faces a class-action lawsuit for allegedly misleading investors about a failed FDA inspection.

Viatris Inc. faces a class-action lawsuit for alleged securities fraud, misleading investors about a failed FDA inspection at its India facility. The lawsuit claims Viatris downplayed the impact as a "minor headwind." After disclosing financial issues related to the inspection, Viatris' stock fell 15.21%. Affected investors can seek compensation through Levi & Korsinsky, with a deadline of June 3, 2025, to join the lawsuit.